


Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group

Sarah S. Long, MD
Chair, Maternal/Pediatric RSV Work Group

ACIP General Meeting
June 22, 2023



Work group members (External)

ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

Lucia Lee (FDA-CBER)

Consultants

Cody Meissner (Dartmouth Geisel School of Medicine)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

Kevin Ault (Western Michigan University)

Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O'Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

GRADE/EtR consultants

Doug Campos-Outcalt

Rebecca Morgan

Work group members (CDC)

CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Melissa Coughlin

Jamison Pike

Lauren Roper

Amber Winn

Chris Taylor

Tami Skoff

Angie Campbell

Michael Melgar

Amanda Payne

Nicole Dowling

Noelle Molinari

Claire Midgley

Fiona Havers

Pragna Patel

Andrea Sharma

Amadea Britton

Ruth Link-Gelles

Danielle Moulia

Megan Wallace

Monica Godfrey

Karen Broder

Naomi Tepper

Hannah Rosenblum

Heidi Moline

Derrell Powers

Raigan Wheeler

Sally Ezra

Elizabeth Greene

A. Patricia Wodi

Neil Murthy

Christine Olson

Anne Hause

Andrew Leidner

David Shay

CDC ACIP Staff

Melinda Wharton

Stephanie Thomas

Jessica MacNeil

Previous maternal/pediatric RSV ACIP presentations

- Epidemiology and burden of RSV in infants
- Virology and immunology of RSV
- Safety and efficacy of nirsevimab
- Cost effectiveness analysis for nirsevimab – CDC model
- Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model
- Evidence to Recommendations framework for nirsevimab
- Clinical considerations for nirsevimab
- Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine

Agenda: Thursday June 22, 2023

- Economic Analysis of RSVpreF in Pediatric Populations
Dr. David Hutton (University of Michigan)
- Evidence to Recommendations Framework for Pfizer Maternal RSVpreF Vaccine
Dr. Katherine Fleming-Dutra (CDC)
- Economics of combined use of Pfizer maternal RSVpreF vaccine and nirsevimab
Dr. David Hutton (University of Michigan)
- Clinical considerations for RSVpreF maternal vaccine and nirsevimab
Dr. Jefferson Jones (CDC)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

